Director, Cyclotron/PET Radiopharmaceutical Production Facility
Mallinckrodt Institute of Radiology (MIR) at Washington University
April 17, 2018
St. Louis, Missouri
Commensurate with experience.
Full Time - Experienced
Academic / Research
The Mallinckrodt Institute of Radiology (MIR) at Washington University in St. Louis is recruiting a Director of its Cyclotron/PET Radiopharmaceutical Production Facility. This is a faculty position, with academic rank dependent upon qualifications.
The Cyclotron/PET Radiopharmaceutical Production Facility has been in existence since 1941, has four cyclotrons, and is one of the most advanced. It contains a Good Manufacturing Practices (GMP) Facility and a Radionuclide Production Laboratory (RPL). The GMP facility maintains a portfolio of over 20 human-use radiopharmaceuticals, and is the principal supplier of 18F-FDG to Barnes-Jewish Hospital (BJH), the flag-ship hospital of the Washington University School of Medicine. The RPL is the largest producer of Cu-64 in the world, used for local research and shipped for sale throughout the United States. The Facility also supports a large radiochemistry research initiative at Washington University, to include novel radiotracer development and first-in-human FDA trials.
Washington University provides a comprehensive and competitive benefits package that ensures economic protection against catastrophic losses while employed, a variety of time off and quality-of-life programs and financial assistance in planning for a comfortable retirement. WUSTL's generous benefits include health, retirement and tuition assistance.
We encourage diversity to reflect the rich community in which we live and serve, and we are committed to promoting an environment that is inclusive and welcoming to all individuals. All qualified applicants will receive consideration for employment without regard to race, color, age, religion, sex, sexual orientation, gender identity or expression, national origin, veteran status, disability or genetic information.
Interested candidates should apply through this website:
The desired individual is an accomplished Ph.D. radiochemist or radiopharmacist, with a successful research program in new radiotracer and/or theranostic agent development who has extensive experience in directing cyclotron radiochemistry production operations and standard and solid target production. Evidence of academic productivity is essential, with a strong publication record required, and record of service to national societies and NIH grant funding preferred. A thorough understanding of Nuclear Regulatory Commission (NRC), Food and Drug Administration (FDA), United States Pharmacopeia (USP) and Nuclear Pharmacy regulations and standards is required. In addition to radiochemistry and production oversight, responsibilities include personnel and business operations management.
Internal Number: 04172018
About Mallinckrodt Institute of Radiology (MIR) at Washington University
Mallinckrodt Institute of Radiology at Washington University School of Medicine
Mallinckrodt Institute of Radiology (MIR) is a premier radiological center, providing a full range of diagnostic, therapeutic, and related patient-care services. It is a major resource of Washington University Medical Center, supporting the educational aims of the university and hospitals through teaching programs and supporting and encouraging a variety of basic and applied research, with special emphasis on radiological science. MIR’s mission is complex — it must provide the best cost-effective patient care, educate students to be future leaders in the field, and seek new knowledge to improve diagnosis and treatment of patients. In every respect, MIR desires to achieve excellence at the highest level locally, nationally, and internationally.